Startups raising funds
* ArriVent Biopharma, a biotech whose lead candidate is a mutant-specific EGFR kinase inhibitor, raised $155m in Series B funding. Sofinnova Investments and General Catalyst co-led, and were joined by Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia Capital China, AIHC Capital, Terra Magnum Capital Partners,